NBIX
Price:
$136.87
Market Cap:
$13.86B
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
1996-05-23
Stock Exchange
NASDAQ
Ticker
NBIX
According to Neurocrine Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 36.50. This represents a change of -18.88% compared to the average of 44.99 of the last 4 quarters.
The mean historical PE Ratio of Neurocrine Biosciences, Inc. over the last ten years is 67.34. The current 36.50 PE Ratio has changed 5.32% with respect to the historical average. Over the past ten years (40 quarters), NBIX's PE Ratio was at its highest in in the December 2017 quarter at 249.47. The PE Ratio was at its lowest in in the March 2015 quarter at -669.18.
Average
67.34
Median
36.73
Minimum
-53.75
Maximum
322.70
Discovering the peaks and valleys of Neurocrine Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 310.43%
Maximum Annual PE Ratio = 322.70
Minimum Annual Increase = -773.76%
Minimum Annual PE Ratio = -53.75
Year | PE Ratio | Change |
---|---|---|
2023 | 51.55 | -30.39% |
2022 | 74.06 | -17.64% |
2021 | 89.92 | 310.43% |
2020 | 21.91 | -91.77% |
2019 | 266.19 | -17.51% |
2018 | 322.70 | -773.76% |
2017 | -47.90 | 101.73% |
2016 | -23.74 | -55.83% |
2015 | -53.75 | 95.32% |
2014 | -27.52 | 103.30% |
The current PE Ratio of Neurocrine Biosciences, Inc. (NBIX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
71.85
5-year avg
100.73
10-year avg
67.34
Neurocrine Biosciences, Inc.’s PE Ratio is greater than Amphastar Pharmaceuticals, Inc. (11.74), greater than Collegium Pharmaceutical, Inc. (10.61), greater than Ironwood Pharmaceuticals, Inc. (29.63), greater than ANI Pharmaceuticals, Inc. (-147.44), greater than Deciphera Pharmaceuticals, Inc. (-11.74), greater than Alkermes plc (14.45), greater than Avadel Pharmaceuticals plc (-13.47), greater than Intra-Cellular Therapies, Inc. (-104.35), less than Dynavax Technologies Corporation (82.09), greater than Pacira BioSciences, Inc. (-9.81), greater than Eagle Pharmaceuticals, Inc. (0.19), greater than Prestige Consumer Healthcare Inc. (18.97), greater than Evotec SE (-8.70), greater than Supernus Pharmaceuticals, Inc. (32.67),
Company | PE Ratio | Market cap |
---|---|---|
11.74 | $1.83B | |
10.61 | $939.77M | |
29.63 | $741.73M | |
-147.44 | $1.13B | |
-11.74 | $2.21B | |
14.45 | $4.77B | |
-13.47 | $978.07M | |
-104.35 | $9.03B | |
82.09 | $1.69B | |
-9.81 | $890.91M | |
0.19 | $6.74M | |
18.97 | $3.89B | |
-8.70 | $1.80B | |
32.67 | $1.95B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neurocrine Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Neurocrine Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Neurocrine Biosciences, Inc.'s PE Ratio?
How is the PE Ratio calculated for Neurocrine Biosciences, Inc. (NBIX)?
What is the highest PE Ratio for Neurocrine Biosciences, Inc. (NBIX)?
What is the 3-year average PE Ratio for Neurocrine Biosciences, Inc. (NBIX)?
What is the 5-year average PE Ratio for Neurocrine Biosciences, Inc. (NBIX)?
How does the current PE Ratio for Neurocrine Biosciences, Inc. (NBIX) compare to its historical average?